Shareholder information Dividends per ADS Share price The table below sets out the dividends per ADS in US dollars in the 2007 2006 2005 last five years, translated into US dollars at applicable exchange m m m rates.
The companys share price decreased by 5% in 2007 from a price of 13.44 at 1st January 2007 to 12.79 at 31st December 2007.
This compares with Dividend calendar an increase in the FTSE 100 index of 4% during the year.
The share Fourth quarter 2007 price on 22nd February 2008 was 11.10.
Ex-dividend date 13th February 2008 Market capitalisation Record date 15th February 2008 The market capitalisation, based on shares in issue excluding Treasury Payable 10th April 2008 shares, of GlaxoSmithKline at 31st December 2007 was 70 billion.
At that date GSK was the fifth largest company by market capitalisation First quarter 2008 on the FTSE index.
Ex-dividend date 30th April 2008 Record date 2nd May 2008 SmithKline Beecham plc Floating Rate Unsecured Loan Stock 1990 2010 Payable 10th July 2008 The loan stock is not listed on any exchange but holders may require Second quarter 2008 SmithKline Beecham plc to redeem their loan stock at par, i. e. 1 for every 1 of loan stock held, on the first business day of March, June, Ex-dividend date 30th July 2008 September and December.
Holders wishing to redeem all or part of Record date 1st August 2008 their loan stock should complete the notice on the back of their loan Payable 9th October 2008 stock certificate and return it to the registrar, to arrive at least 30 days before the relevant redemption date.
Third quarter 2008 Ex-dividend date 29th October 2008 Taxation Record date 31st October 2008 General information concerning the UK and US tax effects of share Payable 8th January 2009 ownership is set out in Taxation information for shareholders on page 179.
Internet Dividends Information about the company including details of the share price is available on GSKs website at www.
It continues to increase cash returns to shareholders through its dividend policy.
Dividends Information made available on the website does not constitute part remain an essential component of total shareholder return and GSK of this Annual Report.
is committed to increasing its dividend over the long-term.
Details of the dividends declared, the amount and the payment dates are given Investor relations in Note 16 to the financial statements, Dividends.
Investor Relations may be contacted as follows: Dividends per share UK The table below sets out the dividends per share in the last five 980 Great West Road, Brentford, Middlesex TW8 9GS years.
Tel: 44 0 20 8047 5000 Year pence USA One Franklin Plaza, PO Box 7929, Philadelphia PA 19101 2007 53 Tel: 1 888 825 5249 US toll free 2006 48 Tel: 1 215 751 4000 outside US 2005 44 2004 42 2003 41 GSK Annual Report 2007 I 175 INVESTOR INFORMATION Shareholder Information Shareholder information continued Analysis of shareholdings at 31st December 2007 Number of % of total % of total Number of accounts accounts shares shares Holding of shares Up to 1,000 126,330 71 1 45,130,222 1,001 to 5,000 39,861 23 1 85,399,100 5,001 to 100,000 9,480 5 2 136,988,653 100,001 to 1,000,000 970 1 6 334,350,551 Over 1,000,000 457 90 5,410,718,500 177,098 100 100 6,012,587,026 Held by Nominee companies 30,647 17 73 4,355,052,360 Investment and trust companies 44 1 32,448,597 Insurance companies 13 109,152 Individuals and other corporate bodies 146,391 83 4 266,773,798 BNY Nominees Limited 2 14 854,008,961 Held as Treasury shares by GlaxoSmithKline 1 8 504,194,158 177,098 100 100 6,012,587,026 The Bank of New York Mellons holding held through BNY Nominees Limited represents the companys ADR programme, whereby each ADS represents two Ordinary shares of 25p nominal value.
At 22nd February 2008, BNY Nominees Limited held 854,735,903 Ordinary shares representing 15.59% of the issued share capital at that date.
At 22nd February 2008, the number of holders of shares in the USA was 1,108 with holdings of 1,393,956 shares, and the number of registered holders of the ADRs was 37,026 with holdings of 427,367,951 ADRs.
Certain of these shares and ADRs were held by brokers or other nominees.
As a result the number of holders of record or registered holders in the USA is not representative of the number of beneficial holders or of the residence of beneficial holders.
Documents on display The Memorandum and Articles of Association of the company and other documents referred to in this Annual Report are available for inspection at the Registered Office of the company.
Publications In late March 2008 GSK will publish on the website its Corporate Responsibility Report covering performance in areas including community investment, ethics and integrity, access to medicines, R&D and environment health and safety.
Exchange controls and other limitations affecting security holders There are currently no UK laws, decrees or regulations restricting the import or export of capital or affecting the remittance of dividends or other payments to holders of the companys shares who are non-residents of the UK.
There are no limitations relating only to non-residents of the UK under English law or the companys Memorandum and Articles of Association on the right to be a holder of, and to vote in respect of, the companys shares.
176 I GSK Annual Report 2007 INVESTOR INFORMATION Shareholder Information Shareholder information continued Nature of trading market Annual General Meeting 2008 The Ordinary shares of the company were listed on the London Stock The Queen Elizabeth II Conference Centre, 21st May 2008 Exchange on 27th December 2000.
The shares were also listed on Broad Sanctuary, Westminster, the New York Stock Exchange NYSE in the form of American London SW1P 3EE Depositary Shares ADSs from the same date.
The Annual General Meeting is the companys principal forum for The following tables set out, for the periods indicated, the high and communication with private shareholders.
In addition to the formal low middle market closing quotations in pence for the shares on the business there will be a presentation by the Chief Executive Officer London Stock Exchange, and the high and low last reported sales on the performance of the Group and its future development.
There prices in US dollars for the ADSs on the NYSE.
will be opportunity for questions to the Board, and the Chairmen of the Boards committees will take questions on matters relating to Pence per share GlaxoSmithKline those committees.
High Low Investors holding shares in the company through a nominee service Quarter ended 31st March 2008 1385 1070 should arrange with that nominee service to be appointed as a February 2008 1184 1070 corporate representative or proxy in respect of their shareholding in January 2008 1385 1174 order to attend and vote at the meeting.
December 2007 1323 1272 ADR holders wishing to attend the meeting must obtain a proxy November 2007 1288 1160 from The Bank of New York Mellon which will enable them to October 2007 1333 1232 attend and vote on the business to be transacted.
ADR holders may September 2007 1341 1297 instruct The Bank of New York Mellon as to the way in which the Quarter ended 31st December 2007 1333 1160 shares represented by their ADRs should be voted by completing and Quarter ended 30th September 2007 1341 1215 returning the voting card provided by the bank in accordance with Quarter ended 30th June 2007 1488 1272 the instructions given.
Quarter ended 31st March 2007 1493 1344 Quarter ended 31st December 2006 1511 1326 Financial reporting Quarter ended 30th September 2006 1540 1418 Quarter ended 30th June 2006 1557 1455 Financial reporting calendar 2008 Quarter ended 31st March 2006 1577 1424 Announcement of 1st Quarter Results April 2008 Year ended 31st December 2005 1544 1175 Announcement of 2nd Quarter Results July 2008 Year ended 31st December 2004 1299 1042 Announcement of 3rd Quarter Results October 2008 Year ended 31st December 2003 1390 1000 Preliminary Announcement of Annual Results February 2009 US dollars per ADS Publication of Annual Report Review February March 2009 High Low Results announcements Quarter ended 31st March 2008 54.36 42.16 Results announcements are issued to the London Stock Exchange February 2008 47.01 42.16 and are available on its news service.
Shortly afterwards, they are January 2008 54.36 46.77 issued to the media, are made available on the website and sent to December 2007 53.93 50.39 the US Securities and Exchange Commission and the NYSE.
November 2007 52.68 47.87 October 2007 54.14 50.52 Financial reports September 2007 54.23 52.22 The company publishes an Annual Report and, for the investor not Quarter ended 31st December 2007 54.14 47.87 needing the full detail of the Report, an Annual Review.
These are Quarter ended 30th September 2007 54.23 49.43 available from the date of publication on the website.
Quarter ended 30th June 2007 59.35 51.28 The Annual Review is sent to all shareholders.
Shareholders may Quarter ended 31st March 2007 58.37 52.66 also elect to receive the Annual Report by writing to the companys Quarter ended 31st December 2006 56.20 51.41 registrars.
Alternatively shareholders may elect to receive notification Quarter ended 30th September 2006 57.01 53.23 by email of the publication of financial reports by registering on Quarter ended 30th June 2006 58.38 51.48 www.
Quarter ended 31st March 2006 54.94 50.15 Copies of previous financial reports are available on GSKs website.
Year ended 31st December 2005 53.53 44.48 Printed copies can be obtained from the registrars in the UK and from Year ended 31st December 2004 47.50 39.04 the GSK Response Center in the USA.
Year ended 31st December 2003 47.40 32.75 Queries relating to receipt of duplicate copies of GSKs publications to 22nd February 2008 should be addressed to the registrars.
GSK Annual Report 2007 I 177 INVESTOR INFORMATION Shareholder Information Shareholder information continued Ordinary shares The companys shares are listed on the London Stock Exchange.
Registrar The companys registrars are: Equiniti Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA www.
co. uk Tel: 0871 384 2991 inside the UK Tel: 44 0 121 415 7067 outside the UK Equiniti also provide the following services: GlaxoSmithKline Investment Plan GlaxoSmithKline Individual Savings Account GlaxoSmithKline Corporate Sponsored Nominee Shareview service Shareview dealing service Dividend reinvestment plan Shareview dealing service Shareholders may buy or sell shares by internet or telephone through Shareview dealing, a share dealing service provided by Equiniti.
For internet purchases and sales log on to www.
co. uk dealing and for telephone purchases and sales call 0871 384 2020 inside the UK only between 8.00am and 4.30pm, Monday to Friday.
Glaxo Wellcome and SmithKline Beecham corporate PEPs The Share Centre Limited Oxford House, Oxford Road, Aylesbury, Bucks HP21 8SZ Tel: 44 0 1296 414141 The provision of the details above is not intended to be an invitation or inducement to engage in an investment activity.
Advice on share dealing should be obtained from a stockbroker or independent financial adviser.
American Depositary Shares The companys shares are listed on the NYSE in the form of American Depositary Shares and these are evidenced by American Depositary Receipts ADRs, each one of which represents two Ordinary shares.
In general, the NYSEs rules permit the company to follow UK corporate governance practices instead of those that apply in the USA, provided that the company explains any signi cant variations.
This explanation is provided on the companys website.
ADR programme administrator The ADR programme is administered by: The Bank of New York Mellon Shareholder Relations PO Box 11258, Church Street Station New York NY 10286-1258 www.
com Tel: 1 877 353 1154 US toll free Tel: 1 212 815 3700 outside US The administrators also provide Global BuyDIRECT, a direct ADS purchase sale and dividend reinvestment plan for ADR holders.
GSK Response Center Tel: 1 888 825 5249 US toll free 178 I GSK Annual Report 2007 INVESTOR INFORMATION Shareholder information
